DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company"
IMMU: 2.35 (-0.05)
IMMUNOMEDICS, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
BusinessWire - Mon Jun 20, 4:52PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. (Nasdaq: IMMU) ("Immunomedics" or the "Company"
IMMU: 2.35 (-0.05)
INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Immunomedics Inc. And Advises Investors With Losses to Contact the Firm
BusinessWire - Mon Jun 20, 11:12AM CDT
Lundin Law PC announces it is investigating claims against Immunomedics Inc. ("Immunomedics" or the "Company"
IMMU: 2.35 (-0.05)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 -- IMMU
Marketwired - Mon Jun 20, 10:05AM CDT
NEW YORK, NY--(Marketwired - June 20, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 2.35 (-0.05)
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc.
BusinessWire - Fri Jun 17, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
IMMU: 2.35 (-0.05)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.35 (-0.05), HCP: 34.23 (+0.18), UNIS: 3.19 (-0.01), CBL: 9.88 (+0.13), INFI: 1.31 (-0.01), EGRX: 38.97 (+0.67), NVCN: 0.56 (-0.03)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immunomedics, Inc. -- IMMU
GlobeNewswire - Thu Jun 16, 4:11PM CDT
Rigrodsky & Long, P.A.:
IMMU: 2.35 (-0.05)
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Investigation of Immunomedics Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 15, 8:59PM CDT
Lundin Law PC announces it is investigating claims against Immunomedics Inc. ("Immunomedics" or the "Company"
IMMU: 2.35 (-0.05)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Immunomedics, Inc. and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
GlobeNewswire - Tue Jun 14, 1:12PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. (NASDAQ:IMMU) securities between April 20, 2016 and June 2, 2016.
IMMU: 2.35 (-0.05)
IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc. - IMMU
GlobeNewswire - Mon Jun 13, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
IMMU: 2.35 (-0.05)
Robbins Arroyo LLP: Immunomedics, Inc. (IMMU) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Mon Jun 13, 8:14PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Immunomedics, Inc. (NASDAQGM: IMMU) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Immunomedics securities between April 20, 2016 and June 2, 2016, for alleged violations of the Securities Exchange Act of 1934 by Immunomedics' officers and directors. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. Among other product candidates, the company is developing the antibody-drug conjugate product IMMU-132 ("IMMU-132"
IMMU: 2.35 (-0.05)